此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

AMPLATZER Cardiac Plug Clinical Trial

2020年4月2日 更新者:Abbott Medical Devices

Amplatzer Cardiac Plug Clinical Trial

The objective of this study is to evaluate the safety and effectiveness of the ACP in subjects with nonvalvular atrial fibrillation by demonstrating that the device is non-inferior to optimal medical therapy (OMT) with respect to the primary effectiveness endpoint and superior to OMT with respect to primary safety endpoint.

研究概览

研究类型

介入性

注册 (实际的)

97

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Los Angeles、California、美国、90048
        • Cedars-Sinai Medical Center
      • Los Angeles、California、美国、90017
        • Good Samaritan Hospital
    • Colorado
      • Aurora、Colorado、美国、80045
        • University of Colorado Denver
      • Littleton、Colorado、美国、80120
        • South Denver Cardiology Associates
    • Georgia
      • Atlanta、Georgia、美国、30308
        • Emory Midtown Hospital and Emory University Hospital
      • Atlanta、Georgia、美国
        • St. Joseph's Hospital and Research Institute
    • Iowa
      • Iowa City、Iowa、美国、52242
        • University of Iowa Hospitals & Clinics
    • Kentucky
      • Lexington、Kentucky、美国、40506
        • University of Kentucky
    • Michigan
      • Detroit、Michigan、美国、48202
        • Henry Ford Hospital
      • Grand Rapids、Michigan、美国、49503
        • Spectrum Health
      • Southfield、Michigan、美国、48075
        • Providence Hospital
    • Minnesota
      • Saint Cloud、Minnesota、美国、56303
        • St. Cloud Hospital/CentraCare Heart and Vascular Clinic
      • Saint Paul、Minnesota、美国、55102
        • HealthEast St. Joseph's Hospital
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • University of Pennsylvania
      • York、Pennsylvania、美国、17405
        • York Hospital
    • South Carolina
      • Charleston、South Carolina、美国、29401
        • Roper Hospital/PMG Research of Charleston
    • Texas
      • Houston、Texas、美国、77030
        • Memorial Hermann Hospital
    • Wisconsin
      • Wausau、Wisconsin、美国、54401
        • Aspirus Heart & Vascular Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Subject must have a documented history of paroxysmal, persistent or permanent nonvalvular atrial fibrillation
  • Subject must be ≥18 years of age
  • Subject must be on warfarin or dabigatran therapy
  • Subject must be eligible for long term warfarin or dabigatran therapy
  • Subject must have a CHADS(2) score of 2 or greater

Summary of Exclusion Criteria:

  • Subject who requires warfarin or dabigatran for a condition other than AF
  • Subject who is on clopidogrel or another P2Y12 platelet inhibitor such as prasugrel or ticagrelor
  • Subject who has an absolute or relative contraindication to aspirin, or warfarin and dabigatran
  • Subject with a New York Heart Association (NYHA) classification equal to IV
  • Subject with an implanted or surgical repair atrial septal defect (ASD) device or patent foramen ovale (PFO) device
  • Subject with aortic or mitral valve regurgitation of grade 2+ or greater
  • Subject with left ventricular ejection fraction (LVEF) ≤30
  • Subject with mitral or aortic prosthetic valve
  • Subject with a history of hemorrhagic or aneurysmal stroke
  • Subject with a history of previous radio frequency (RF) ablation for atrial fibrillation
  • Subject with a body mass index (BMI) ≥40
  • Subject with a history of acute or recent MI, or unstable angina, or coronary artery bypass graft surgery (within 6 months)
  • Subject who is on aspirin dose therapy greater than 81mg/day at time of enrollment

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Device
AMPLATZER Cardiac Plug
AMPLATZER Cardiac Plug is a percutaneous transcatheter device
有源比较器:Optimal Medical Therapy (control)
Warfarin Dabigatran
AMPLATZER Cardiac Plug is a percutaneous transcatheter device

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Acute Safety - Procedure Related SAEs From Randomization Through Discharge For Device Arm Only
大体时间:From Randomization to Discharge Visit

An analysis comparing the rate of procedure related serious adverse events that occur in the device arm to a performance goal determined from literature reported rates for similar procedural techniques.

The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT).

However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm below. The secondary endpoint analysis requirement was removed from the protocol.

From Randomization to Discharge Visit
Long-term Safety - Device Arm Only
大体时间:Randomization to 2 year follow-up

All-Cause Mortality and Major Bleeds Through 2 years in device arm subjects only. The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT).

However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm. The secondary endpoint analysis requirement was removed from the protocol.

Randomization to 2 year follow-up
Effectiveness Endpoint - Device Arm Only
大体时间:Randomization through 2 year follow up

Occurrence of ischemic stroke and peripheral thromboembolism in the device arm. The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT).

However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm. The secondary endpoint analysis requirement was removed from the protocol.

Randomization through 2 year follow up

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2010年4月26日

初级完成 (实际的)

2018年12月6日

研究完成 (实际的)

2018年12月6日

研究注册日期

首次提交

2010年5月5日

首先提交符合 QC 标准的

2010年5月5日

首次发布 (估计)

2010年5月6日

研究记录更新

最后更新发布 (实际的)

2020年4月14日

上次提交的符合 QC 标准的更新

2020年4月2日

最后验证

2020年4月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅